Chesapeake Wealth Management Sells 45 Shares of Eli Lilly and Company $LLY

Chesapeake Wealth Management lessened its position in Eli Lilly and Company (NYSE:LLY) by 1.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,095 shares of the company’s stock after selling 45 shares during the quarter. Chesapeake Wealth Management’s holdings in Eli Lilly and Company were worth $2,413,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in LLY. Brighton Jones LLC lifted its holdings in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after acquiring an additional 85 shares during the last quarter. GAMMA Investing LLC increased its stake in Eli Lilly and Company by 25.8% in the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock worth $14,866,000 after buying an additional 3,696 shares during the period. Finally, Warner Financial Inc. lifted its holdings in Eli Lilly and Company by 129.2% during the 1st quarter. Warner Financial Inc. now owns 1,123 shares of the company’s stock valued at $927,000 after buying an additional 633 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Morgan Stanley decreased their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Finally, HSBC lifted their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $948.06.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Jamere Jackson bought 200 shares of the stock in a transaction on Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Trading Up 1.7%

NYSE LLY opened at $826.20 on Thursday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $781.97 billion, a price-to-earnings ratio of 54.00, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47. The company’s 50-day simple moving average is $745.96 and its two-hundred day simple moving average is $766.28. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.